Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -4.36% is 33% above its 5-year average of -6.48%, near the high end of its 5-year range (-44.06%–3.84%).
131.42% below its 12-month average of -1.88%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 3.84%.
EBITDA MARGIN
-4.36%
EBITDA MARGIN AVG TTM
-1.88%
EBITDA MARGIN AVG 3Y
-4.23%
EBITDA MARGIN AVG 5Y
-6.48%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-131.42%
CURRENT VS 3Y AVG
-3.05%
CURRENT VS 5Y AVG
+32.75%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Clover Health Investments, Corp.
Market Cap
$2.43B
EBITDA Margin
-4.36%
TTM Avg
-1.88%
3Y Avg
-4.23%
5Y Avg
-6.48%
Market Cap
$2.34B
EBITDA Margin
39.11%
TTM Avg
36.80%
3Y Avg
16.06%
5Y Avg
-24.25%
Market Cap
$2.51B
EBITDA Margin
-755.79%
TTM Avg
-753.93%
3Y Avg
-709.93%
5Y Avg
-1157.85%
Market Cap
$2.64B
EBITDA Margin
-270.04%
TTM Avg
-444.88%
3Y Avg
-365.27%
5Y Avg
-89273.54%
Market Cap
$2.64B
EBITDA Margin
-37.02%
TTM Avg
-37.02%
3Y Avg
-37.02%
5Y Avg
-37.02%
Market Cap
$2.17B
EBITDA Margin
-18934.67%
TTM Avg
-10834.15%
3Y Avg
-7159.00%
5Y Avg
-5150.48%
Market Cap
$2.69B
EBITDA Margin
17.42%
TTM Avg
19.36%
3Y Avg
20.74%
5Y Avg
18.34%
Market Cap
$2.69B
EBITDA Margin
11.88%
TTM Avg
11.88%
3Y Avg
7.44%
5Y Avg
-2.29%
Market Cap
$2.11B
EBITDA Margin
10.90%
TTM Avg
10.48%
3Y Avg
9.90%
5Y Avg
9.38%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clover Health Investments, Corp. (CLOV) | $2.43B | -4.36% | -1.88% | -4.23% | -6.48% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.34B | 39.11% | 36.80% | 16.06% | -24.25% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.51B | -755.79% | -753.93% | -709.93% | -1157.85% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.64B | -270.04% | -444.88% | -365.27% | -89273.54% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.64B | -37.02% | -37.02% | -37.02% | -37.02% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.17B | -18934.67% | -10834.15% | -7159.00% | -5150.48% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | 17.42% | 19.36% | 20.74% | 18.34% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 11.88% | 11.88% | 7.44% | -2.29% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 10.90% | 10.48% | 9.90% | 9.38% |
| Alvotech (ALVO)vs › | $2.07B | 19.79% | 20.20% | -178.47% | -247.76% |
Gross Margin
18.6%
EBITDA Margin
-4.4%
Operating Margin
-0.7%
Net Margin
-0.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 3.84% |
| 2026-03-31 | 3.72% |
| 2025-12-31 | -10.03% |
| 2025-09-30 | -4.83% |
| 2025-06-30 | -2.13% |
| 2025-03-31 | -0.17% |
| 2024-12-31 | -6.26% |
| 2024-09-30 | -2.55% |
| 2024-06-30 | 2.11% |
| 2024-03-31 | -6.45% |
| 2023-12-31 | -12.74% |
| 2023-09-30 | -10.80% |
| 2023-06-30 | -8.71% |
| 2023-03-31 | -24.66% |
| 2022-09-30 | -8.58% |
| 2022-06-30 | -12.06% |
| 2022-03-31 | -9.91% |
| 2021-12-31 | -43.04% |
| 2021-09-30 | -34.91% |
| 2021-06-30 | -44.06% |
| 2021-03-31 | -59.37% |
| 2020-12-31 | -40.60% |
| 2020-09-30 | -12.70% |
| 2020-06-30 | 13.55% |
| 2020-03-31 | -16.02% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
